TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Government & Organizations

    Psychopharmacology and Psychiatry Updates

    Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

    Advertise
    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Antipsychotics, Prolactin, and Sexual Side Effects Sep 23, 2026
    Show notes

    In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
    • Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use
    EMERGENT-5: Cobenfy and Treatment Durability Sep 18, 2026
    Show notes

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our membership here
    • Earn 0.5 CME: Quick Take Vol. 85
    • Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
    Antipsychotics and Weight Gain Sep 13, 2026
    Show notes

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
    • Antipsychotic-Induced Weight Gain: Prevention and Management
    EPA vs. DHA: Fish Oil and Treatment-Resistant Depression Sep 08, 2026
    Show notes

    In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms.

    Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 0.75 CMEs: Quick Take Vol. 84
    • Eicosapentaenoic Acid: Effective as Adjunctive for TRD?
    AUD Medications and Hepatic Safety Sep 03, 2026
    Show notes

    In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis.

    Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
    • Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status
    GLP-1 Agonists in Serious Mental Illness: Current Evidence Aug 29, 2026
    Show notes

    In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our membership here
    • Earn 0.75 CMEs: Quick Take Vol. 84
    • GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?
    Gabapentin, Topiramate & Baclofen in AUD Aug 24, 2026
    Show notes

    In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed.

    Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder
    • Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder
    Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good Aug 19, 2026
    Show notes

    In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities.

    Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.

    • Learn more about our membership here
    • Earn 0.75 CMEs: Quick Take Vol. 84
    • Benzodiazepine Tapering: Key Takeaways From New Guidelines
    Disulfiram Unpacked: Efficacy, Risks, and Liver Safety Aug 14, 2026
    Show notes

    In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients?

    Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
    • Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations
    GLP-1s and Lithium: What Clinicians Need to Know Aug 09, 2026
    Show notes

    In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why?

    Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.

    • Learn more about our membership here
    • Earn 0.75 CMEs: Quick Take Vol. 83
    • Can GLP-1 Agonists Elevate Lithium Levels?
    1 2 3 10 Next

    Related Podcasts

    The Joe Rogan Experience

    1

    The Joe Rogan Experience Comedy
    More Perfect

    2

    More Perfect Government
    Casefile True Crime

    3

    Casefile True Crime Games & Hobbies
    Reply All

    4

    Reply All Games & Hobbies
    You Must Remember This

    5

    You Must Remember This Games & Hobbies
    Real Time with Bill Maher

    6

    Real Time with Bill Maher Games & Hobbies
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights